Compare ImmunityBio Inc. Common Stock (IBRX) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Levi Strauss & Co. — how do they compare? ImmunityBio Inc. Common Stock trades at $9.99 (market cap $10.51B), while Levi Strauss & Co. trades at $19.02 (market cap $7.31B). The key difference: ImmunityBio Inc. Common Stock is the larger of the two by market cap, and Levi Strauss & Co. pays a 3.36% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Levi Strauss & Co. for 70 Days on average.
| IBRX | LEVI | |
|---|---|---|
Market Cap | $10.51B | $7.31B |
Volume | 10,445,785 | 13,683,095 |
Sector | Health | Consumer Cyclical |
52-Week High | $11.55 | $25.53 |
52-Week Low | $1.98 | $17.92 |
Typical Hold Time | 0 Days | 70 Days |
Enterprise Value | $10.97B | $8.86B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Levi Strauss (LEVI) trades at $19.51, down 4.97% today, amid a bearish technical signal but strong fundamentals. The company has consistently beaten earnings estimates, with Q3 2026 EPS of $0.48 exceeding expectations. Valuation metrics appear attractive with a P/E of 12.84 and P/S of 1.15, while profitability remains robust with a net income margin of 9.66% and ROE of 29.31%. Recent news highlights a new CFO appointment and positive analyst sentiment on denim demand.
The outlook is positive given earnings momentum and analyst consensus, with a price target of $27.80 implying significant upside. Risks include competitive pressures and recent cybersecurity incidents, but strong cash flow and dividend payments support shareholder value. Wall Street sentiment is bullish with 79% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
